Research

The Weiss lab studies the biology and treatment of cancers of the nervous system, with a longstanding focus on MYC/MYCN-driven pediatric cancers. We combine mouse genetics, human pluripotent stem cell–derived tumor models, functional genomics, proteomics, and preclinical therapeutics to understand how oncogenic drivers interact with developmental programs, cell states, and the tumor microenvironment—and how these interactions create therapeutic vulnerabilities.

Our major disease interests include neuroblastoma, medulloblastoma, ependymoma, and glioblastoma.

MYC/MYCN Biology and Therapeutics

MYC and MYCN have long been central to our research. We study how these oncogenes reshape translational control and protein networks and seek dependencies that can be exploited therapeutically.

Recent work from our lab showed that N-myc selectively remodels translation in medulloblastoma, creating vulnerabilities in protein homeostasis. We also used human stem cell–derived neuroblastoma models to show that oncogenic ALK cooperates with MYCN through a POSTN–WNT signaling circuit.

We are extending this work using proteomic and functional approaches to identify therapeutic vulnerabilities created by MYC/MYCN. As part of KOODAC, a Cancer Grand Challenges team, we are also developing targeted protein degradation strategies against oncogenic drivers of childhood cancers.

Developmental Origins and Tumor Models

Pediatric cancers arise in developing tissues. We derive neural progenitor populations from human induced pluripotent stem cells (iPSCs) and introduce defined oncogenic alterations to reconstruct tumor initiation in a developmentally appropriate context.

We use these systems to model neuroblastoma, medulloblastoma, and ependymoma. Current studies include MYC-driven Group 3 medulloblastoma and fusion-driven supratentorial ependymoma. We are particularly interested in how oncogenic drivers interact with developmental cell states to initiate and maintain tumors.

We also study developmental and epigenetic mechanisms in medulloblastoma, including dysregulation of the core-binding factor complex in Group 4 disease.

Tumor Evolution and Therapy Resistance

Tumor cells can occupy distinct developmental and transcriptional states and change those states as tumors progress or encounter therapy. In neuroblastoma, we study adrenergic and mesenchymal cell states and how cell-state plasticity influences tumor behavior, therapeutic response, and resistance.

We also use human iPSC-derived models of MYC-driven Group 3 medulloblastoma to study primary tumor growth and leptomeningeal metastasis, with the goal of identifying mechanisms that enable tumor dissemination and metastatic growth.

In medulloblastoma, we combine in vivo Perturb-seq, functional genomics, and preclinical therapeutic testing to identify cell states and molecular programs that allow tumors to survive treatment and develop resistance.

Tumor Immunity

We study how MYCN shapes the immune microenvironment of neuroblastoma and contributes to resistance to immunotherapy. Using Mycn-nGEMM, our immunocompetent, non-germline model of neuroblastoma, we showed that MYCN-driven tumors establish a macrophage-rich, immunosuppressive microenvironment. PD-L1 blockade depleted immunosuppressive macrophages and increased T-cell infiltration, while the addition of a CD40 agonist further prolonged survival.

We are now using Mycn-nGEMM to define interactions between MYCN-driven tumors and the immune microenvironment and to develop new therapeutic strategies that enhance antitumor immunity. Our goal is to overcome the immunosuppressive tumor microenvironment and improve the effectiveness of immunotherapy in MYCN-driven neuroblastoma.

Glioblastoma and Brain-Restricted Therapeutics

In glioblastoma, we study new strategies to target oncogenic signaling and expand the therapeutic window of molecularly targeted therapies. Recent work from our lab showed that EGFR and EGFRvIII co-opt innate immune signaling through TLR2, promoting tumor progression and immune evasion.

We are developing binary pharmacology, an approach designed to restrict kinase inhibition selectively to the brain. By maintaining potent target inhibition in the central nervous system while limiting drug activity in peripheral tissues, we aim to overcome systemic toxicities that have constrained targeted therapies for brain tumors.

We are also extending these concepts using next-generation RAS and mTOR inhibitors to develop new therapeutic strategies and rational combinations that target signaling dependencies in glioblastoma.

Across these studies, MYC/MYCN-driven pediatric neuro-oncology remains a central theme of the Weiss lab. By understanding how oncogenic drivers interact with development, tumor evolution, and the microenvironment, we aim to translate these insights into more effective therapies.

 

Last updated: November 2026